Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Uric Acid Oxidase in Healthy Adults and Hyperuricemia Volunteers
NCT05226013Phase 1Unknown
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hyperuricemia comparing PEGylated Urate Oxidase with Placebo (2 arms). Primary endpoints: Peak Plasma Concentration at 500 days, Maximum Tolerated Dose at 500 days and 1 more. Status: unknown.
02
Drugs
polyglycolated urate oxidase
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT05226013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226013.